PA8659101A1 - Uso de colorantes de cianina para el diagnostco de enfermedades proliferativas - Google Patents
Uso de colorantes de cianina para el diagnostco de enfermedades proliferativasInfo
- Publication number
- PA8659101A1 PA8659101A1 PA20068659101A PA8659101A PA8659101A1 PA 8659101 A1 PA8659101 A1 PA 8659101A1 PA 20068659101 A PA20068659101 A PA 20068659101A PA 8659101 A PA8659101 A PA 8659101A PA 8659101 A1 PA8659101 A1 PA 8659101A1
- Authority
- PA
- Panama
- Prior art keywords
- diagnost
- proliferative diseases
- cyanine
- colors
- cyanine colors
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 title abstract 2
- 239000003086 colorant Substances 0.000 title 1
- 230000037396 body weight Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
USO DEL COLORANTE DE CIANINA SF64 PARA EL DIAGNOSTICO DE ENFERMEDADES PROLIFERATIVAS CON UNA ADMINISTRACION QUE COMPRENDE MENOS QUE 5MG/KG DE PESO CORPORAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05000276A EP1679082A1 (en) | 2005-01-07 | 2005-01-07 | Use of cyanine dyes for the diagnosis of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8659101A1 true PA8659101A1 (es) | 2006-09-08 |
Family
ID=34933224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20068659101A PA8659101A1 (es) | 2005-01-07 | 2006-01-06 | Uso de colorantes de cianina para el diagnostco de enfermedades proliferativas |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP1679082A1 (es) |
JP (1) | JP5578765B2 (es) |
KR (1) | KR20070092270A (es) |
CN (1) | CN101128218A (es) |
AR (1) | AR052190A1 (es) |
AU (1) | AU2006204496A1 (es) |
BR (1) | BRPI0606411A2 (es) |
CA (1) | CA2594390C (es) |
CR (1) | CR9232A (es) |
DO (1) | DOP2006000005A (es) |
GT (1) | GT200600001A (es) |
IL (1) | IL182499A0 (es) |
MX (1) | MX2007008300A (es) |
NO (1) | NO20074036L (es) |
NZ (1) | NZ554917A (es) |
PA (1) | PA8659101A1 (es) |
PE (2) | PE20060872A1 (es) |
RU (1) | RU2007129919A (es) |
TW (1) | TW200635612A (es) |
UA (1) | UA89976C2 (es) |
UY (1) | UY29323A1 (es) |
WO (1) | WO2006072580A1 (es) |
ZA (1) | ZA200706533B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1619501B1 (en) * | 2004-07-22 | 2007-09-26 | Bayer Schering Pharma Aktiengesellschaft | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
EP1679082A1 (en) * | 2005-01-07 | 2006-07-12 | Schering AG | Use of cyanine dyes for the diagnosis of proliferative diseases |
EP1743658A1 (en) * | 2005-07-14 | 2007-01-17 | Schering Aktiengesellschaft | Optical imaging of rheumatoid arthritis |
US20100119457A1 (en) * | 2007-03-30 | 2010-05-13 | Helmut Lenz | Composition of labeled and non-labeled monoclonal antibodies |
US20110262354A1 (en) | 2007-07-13 | 2011-10-27 | Emory University | Cyanine-containing compounds for cancer imaging and treatment |
GB0803477D0 (en) | 2008-02-26 | 2008-04-02 | Ge Healthcare As | Therapy selection method |
CN105288645A (zh) * | 2008-06-13 | 2016-02-03 | 西塞医疗中心 | 用于癌症靶向治疗的小分子配体-药物轭合物 |
GB0814960D0 (en) * | 2008-08-15 | 2008-09-24 | Ge Healthcare As | Method for detecting dysplasia |
US20120226119A1 (en) | 2009-07-09 | 2012-09-06 | Hoffmann-La Roche Inc. | Vivo tumor vasculature imaging |
EP2459053A2 (en) | 2009-07-28 | 2012-06-06 | F. Hoffmann-La Roche AG | Non-invasive in vivo optical imaging method |
EP2470887B1 (en) | 2009-08-28 | 2020-03-11 | VisEn Medical, Inc. | Systems for tomographic imaging in diffuse media using a hybrid inversion technique |
JP2011046663A (ja) | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
JP2011046662A (ja) | 2009-08-28 | 2011-03-10 | Fujifilm Corp | 近赤外蛍光造影剤 |
US8401619B2 (en) | 2009-09-22 | 2013-03-19 | Visen Medical, Inc. | Systems and methods for virtual index-matching of diffusive media |
MX2012012736A (es) | 2010-05-07 | 2013-02-26 | Hoffmann La Roche | Metodo de diagnostico para la deteccion de celulas ex vivo. |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
JP6100704B2 (ja) | 2011-03-07 | 2017-03-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 治療用抗体についてのインビボ試験の手段および方法 |
KR101373108B1 (ko) | 2012-01-20 | 2014-03-27 | 이화여자대학교 산학협력단 | 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법 |
CN102608051B (zh) * | 2012-02-21 | 2015-04-08 | 中国科学院化学研究所 | 用于诊断白血病的试剂盒 |
CN102703569B (zh) * | 2012-05-24 | 2014-04-09 | 中国科学院化学研究所 | 菁染料的新用途 |
CN102706787B (zh) * | 2012-05-24 | 2015-04-08 | 中国科学院化学研究所 | 菁染料的新用途 |
US10743768B2 (en) | 2012-10-15 | 2020-08-18 | Visen Medical, Inc. | Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources |
EP2849743B1 (en) | 2012-10-26 | 2019-09-25 | Canon Kabushiki Kaisha | Cancer cell inhibitory drug and cancer stem-cell detection probe |
WO2014092958A1 (en) * | 2012-12-10 | 2014-06-19 | Molecular Targeting Technologies, Inc. | Compositions and methods of diagnosing ocular diseases |
AU2014373656B2 (en) | 2013-12-31 | 2019-12-05 | Cornell University | Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time |
RU2565645C1 (ru) * | 2014-09-05 | 2015-10-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани |
RU2017122621A (ru) | 2014-12-15 | 2019-01-17 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Циклические пептиды с улучшенной селективностью связывания с нервами, наночастицы, связанные с указанными циклическими пептидами, и их применение для визуализации нервной ткани in vivo в реальном времени |
CN108495655A (zh) | 2015-12-15 | 2018-09-04 | 纪念斯隆凯特琳癌症中心 | 用于组织区分例如用于术中可视化的成像系统和方法 |
US11660354B2 (en) | 2016-11-30 | 2023-05-30 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
CA3095410A1 (en) | 2018-03-30 | 2019-10-03 | Perkinelmer Health Sciences, Inc. | Systems and methods for 3d reconstruction of anatomical organs and inclusions using short-wave infrared (swir) projection tomography |
EP4015004A1 (en) | 2020-12-18 | 2022-06-22 | Phi Pharma SA | Proteoglycan specific branched peptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000095758A (ja) * | 1998-09-18 | 2000-04-04 | Schering Ag | 近赤外蛍光造影剤および蛍光造影方法 |
DE19917713A1 (de) * | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik |
DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
PL376459A1 (en) * | 2003-01-24 | 2005-12-27 | Schering Ag | Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis |
EP1619501B1 (en) * | 2004-07-22 | 2007-09-26 | Bayer Schering Pharma Aktiengesellschaft | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
EP1679082A1 (en) * | 2005-01-07 | 2006-07-12 | Schering AG | Use of cyanine dyes for the diagnosis of proliferative diseases |
-
2005
- 2005-01-07 EP EP05000276A patent/EP1679082A1/en not_active Withdrawn
-
2006
- 2006-01-02 UY UY29323A patent/UY29323A1/es not_active Application Discontinuation
- 2006-01-03 DO DO2006000005A patent/DOP2006000005A/es unknown
- 2006-01-04 GT GT200600001A patent/GT200600001A/es unknown
- 2006-01-05 MX MX2007008300A patent/MX2007008300A/es not_active Application Discontinuation
- 2006-01-05 JP JP2007549858A patent/JP5578765B2/ja active Active
- 2006-01-05 KR KR1020077015555A patent/KR20070092270A/ko not_active Application Discontinuation
- 2006-01-05 EP EP06700474A patent/EP1833513B1/en active Active
- 2006-01-05 PE PE2006000039A patent/PE20060872A1/es not_active Application Discontinuation
- 2006-01-05 CN CNA2006800014277A patent/CN101128218A/zh active Pending
- 2006-01-05 AU AU2006204496A patent/AU2006204496A1/en not_active Abandoned
- 2006-01-05 PE PE2010000020A patent/PE20100449A1/es not_active Application Discontinuation
- 2006-01-05 WO PCT/EP2006/000058 patent/WO2006072580A1/en active Application Filing
- 2006-01-05 RU RU2007129919/15A patent/RU2007129919A/ru not_active Application Discontinuation
- 2006-01-05 NZ NZ554917A patent/NZ554917A/en unknown
- 2006-01-05 BR BRPI0606411-6A patent/BRPI0606411A2/pt not_active IP Right Cessation
- 2006-01-05 UA UAA200708556A patent/UA89976C2/ru unknown
- 2006-01-05 CA CA2594390A patent/CA2594390C/en active Active
- 2006-01-06 PA PA20068659101A patent/PA8659101A1/es unknown
- 2006-01-06 AR ARP060100046A patent/AR052190A1/es unknown
- 2006-01-06 TW TW095100548A patent/TW200635612A/zh unknown
-
2007
- 2007-04-12 IL IL182499A patent/IL182499A0/en unknown
- 2007-07-06 CR CR9232A patent/CR9232A/es not_active Application Discontinuation
- 2007-08-03 NO NO20074036A patent/NO20074036L/no not_active Application Discontinuation
- 2007-08-06 ZA ZA200706533A patent/ZA200706533B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006204496A1 (en) | 2006-07-13 |
UA89976C2 (ru) | 2010-03-25 |
ZA200706533B (en) | 2009-07-29 |
BRPI0606411A2 (pt) | 2009-06-23 |
KR20070092270A (ko) | 2007-09-12 |
EP1679082A1 (en) | 2006-07-12 |
UY29323A1 (es) | 2006-10-02 |
JP2008526802A (ja) | 2008-07-24 |
EP1833513A1 (en) | 2007-09-19 |
AR052190A1 (es) | 2007-03-07 |
RU2007129919A (ru) | 2009-02-20 |
CA2594390A1 (en) | 2006-07-13 |
CR9232A (es) | 2007-11-23 |
GT200600001A (es) | 2006-08-22 |
CA2594390C (en) | 2013-10-22 |
WO2006072580A1 (en) | 2006-07-13 |
DOP2006000005A (es) | 2006-07-15 |
EP1833513B1 (en) | 2013-03-06 |
NZ554917A (en) | 2010-01-29 |
MX2007008300A (es) | 2007-09-07 |
NO20074036L (no) | 2007-08-03 |
JP5578765B2 (ja) | 2014-08-27 |
CN101128218A (zh) | 2008-02-20 |
IL182499A0 (en) | 2007-09-20 |
TW200635612A (en) | 2006-10-16 |
PE20060872A1 (es) | 2006-10-01 |
PE20100449A1 (es) | 2010-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8659101A1 (es) | Uso de colorantes de cianina para el diagnostco de enfermedades proliferativas | |
HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
MA40239B1 (fr) | (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido[1',2':4,5]pyrazino[2,1-b]oxazépin-8-olate de sodium | |
AR060880A1 (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
HN2008001103A (es) | Agentes citotoxicos que comprenden nuevos derivados de tomaimicina | |
CL2012002355A1 (es) | Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih. | |
AR062448A1 (es) | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos | |
CL2012002944A1 (es) | Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
PA8740901A1 (es) | Compuestos organicos | |
CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
CL2008001303A1 (es) | Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer. | |
CL2009000889A1 (es) | Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus. | |
CR20110553A (es) | Terapia complementaria contra el cáncer | |
HN2008000360A (es) | Dispersiones amorfas solidas | |
ECSP099822A (es) | Derivados de guanina policiclicos y sus métodos de uso | |
PA8846101A1 (es) | Anticuerpos del receptor ii anti-tgf-beta | |
CL2012001596A1 (es) | Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva. | |
HN2003000183A (es) | Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
CR11273A (es) | Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica | |
GT200600106A (es) | Agentes endoparasiticidas | |
GT200600077A (es) | Imidazoles sustituidos con heterociclilamida | |
ECSP10010379A (es) | Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina | |
CL2009001089A1 (es) | Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. |